Navigation Links
Hospira Announces Executive Changes
Date:3/1/2013

LAKE FOREST, Ill., March 1, 2013 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced that Royce R. Bedward has been appointed corporate vice president, general counsel and secretary, effective immediately. In his new role, Mr. Bedward will oversee the company's legal department, including litigation, benefits, labor and employment, intellectual property, governance, securities and transactional matters. He will report to Brian Smith , who has served as Hospira's senior vice president and general counsel since its spin-off in 2004, and now assumes the newly created role of chief legal officer, including responsibility for government affairs. Both Mr. Smith and Mr. Bedward will serve as members of the company's senior leadership team, led by F. Michael Ball , chief executive officer.

(Photo: http://photos.prnewswire.com/prnh/20130301/CG69263)

"Royce is an accomplished lawyer and integrity-driven business leader with more than 10 years of experience in the healthcare field and a proven track record of success at Hospira," said Mr. Ball. "We look forward to Royce's many additional contributions, while thanking Brian for his continued service and counsel. Working together, I'm confident that their strong leadership abilities will help position Hospira for a stronger future of sustainable, long-term growth and drive greater value for our stakeholders."

Mr. Bedward, 47, is one of the founding members of Hospira's legal leadership team, joining the company at its inception as its vice president of litigation, and assuming roles of increasing responsibility, most recently holding the position of deputy general counsel and secretary.  Prior to
'/>"/>

SOURCE Hospira, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
2. Hospira Reports First-Quarter 2012 Results
3. Hospira to Present at Upcoming Investor Conferences
4. I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process
5. Hospira and Lancaster General Hospital Honored for Patient Safety Initiatives
6. Hospira to Host Conference Call for Second-quarter 2012 Results
7. Hospira Expands Board of Directors With Election of Dennis M. Fenton
8. Hospira Reports Second-Quarter 2012 Results
9. Hospira to Acquire Active Pharmaceutical Ingredient Manufacturing and R&D Facilities
10. Hospira Reports Third-Quarter 2012 Results
11. Hospira to Present at the J.P. Morgan 31st Annual Healthcare Conference Jan. 8, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , Sept. 3, 2015  The findings of ... raising disturbing questions about the company,s handling of its ... reports.  On September 2 nd , part one ... adverse events, including at least 27 fatalities, have been ... a confidential study commissioned by C.R. Bard in 2004 ...
(Date:9/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/4q3mv2/investigation ) ... on China Olmesartan Market, 2010-2019" report to their ... successfully developed by Sankyo Pharmaceuticals Co., Ltd and was ... was approved by FDA to enter the American market ... drug in the world after it succeeded in the ...
(Date:9/3/2015)... Sept. 3, 2015 Research and Markets ... the "Investigation Report on China Tamsulosin Market, ... Compared with other a1- adrenergic receptor blockers, ... and lower risk of urinary tract infections and ... its debut in 1993 in Japan ...
Breaking Medicine Technology:IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 2IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 3China Olmesartan Investigation Market Report 2010-2019 2China Tamsulosin Market Investigation Report 2015 2
... 2010 ViroPharma Incorporated (Nasdaq: VPHM ) ... Cinryze ® (C1 esterase inhibitor [human]) at the ... (WAO), December 5 through 8 in Dubai, UAE.   ... these data, which were first presented at the November ...
... Healthcare, a world-leading developer, manufacturer and marketer of innovative ... that in connection with a refinancing of its debt ... in combination with new senior secured credit facilities, it ... Senior Notes. The offering of the new notes will ...
Cached Medicine Technology:Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 2Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 3Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 4Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 5Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 6Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 7Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 8Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 9ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering 2ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering 3
(Date:9/3/2015)... ... 03, 2015 , ... Girl’s Night Out to benefit Core Compassion Project will ... Kate Road in Monroe, North Carolina. The event food will be provided ... Kate Clyde’s offers off-premise catering and event services from casual to elegant. They are ...
(Date:9/3/2015)... ... September 03, 2015 , ... For the second ... Annual Inc. 5000 list of fastest-growing private companies in America. President and ... the nation's companies have demonstrated such remarkably consistent high growth, particularly in the ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... providers, has been retained to lead a national chief executive officer ... search firms in the healthcare industry, B. E. Smith has recently placed more ...
(Date:9/3/2015)... ... 03, 2015 , ... According to an Oncology Nurse Advisor article ... patients with oropharyngeal cancer (oral cancer) to be successfully diagnosed and treated for relapses ... HPV infections, which have a high rate of success in treatment and elimination of ...
(Date:9/3/2015)... ... 03, 2015 , ... As a result of the Patient ... health insurance plans, more employers are moving to a self-funded model for pharmacy ... 2014 United Benefit Advisors (UBA) Health Plan Survey. , UBA’s survey, the nation’s ...
Breaking Medicine News(10 mins):Health News:Girl’s Night Out, with Food From Kate Clyde's Catered Creations, to Benefit Core Compassion Project 2Health News:Inc. 5000 Includes Intellicure, Inc., Two Years in a Row 2Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 3Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 2Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4
... N.J., March 27 Zydus Pharmaceuticals announced today that ... and Drug Administration (FDA) for its Abbreviated New Drug ... and 200mg. This product is available for immediate ... patients 10 years old or older with partial onset ...
... Michigan, there are not enough jobs in manufacturing and ... to overshadow supply is health care, particularly physicians.The health ... difficulty of becoming a doctor have led to a ... projected to get worse, according to the Michigan State ...
... Stats show safety programs need to be extended to others ... (HealthDay News) -- Only one-third of people killed in fatal ... report shows. , The other two-thirds of victims are passengers, ... to the AAA Foundation for Traffic Safety. , "For every ...
... Women,s Voices for the Health Care We NeedNEW YORK, March ... debate the merits and costs of health reform, women around ... our families. For many women and our families, health reform ... York City will speak out publicly about the problems they ...
... of a program established in Uganda last year, the ... (HVO) have again partnered to launch a new hematology ... Empresa De Seguros De Salud (EsSalud). The goal of ... clinicians, laboratory technicians, technologists, and students. This training will ...
... unlocks the virus from latent state , , FRIDAY, March 27 ... in the ongoing quest for a treatment, and possibly a ... as VP16 is apparently responsible for pushing herpes out of ... , Experts estimate that 70 percent to 90 percent of ...
Cached Medicine News:Health News:As Physician Shortage Looms, Recognize Your Doctor On March 30, National Doctors' Day 2Health News:Most Fatalities in Teen Crashes Are Not the Drivers 2Health News:Women's Speak-Out for Action on Health Care Reform 2Health News:ASH and HVO Partner to Launch Hematology Program in Peru 2Health News:ASH and HVO Partner to Launch Hematology Program in Peru 3Health News:Treatment Target for Herpes Pinpointed 2
... Controls are liquid controls designed ... test procedures that detect Chlamydia ... they are specimen specific, they ... urine or endocervical/urethral swabs throughout ...
Liquichek Pediatric Control is a product designed to monitor important analytes for neonatal testing. This control monitors four bilirubin parameters at two clinically significant levels....
Liquid Assayed and Unassayed Multiqual Controls are comprehensive, liquid, human serum based chemistry controls, available in three levels....
Liquichek Therapeutic Drug Monitoring Control (TDM) is a liquid assayed control containing a comprehensive menu of therapeutic drugs, as well as many common ligands. Available in three levels....
Medicine Products: